by CheckRare Staff | Feb 13, 2026
PRIMA Clinical Trial Bradley J. Monk, MD, Medical Director, Florida Cancer Specialists and Research Institute, West Palm Beach, and Founder of GOG Partners, discusses the clinical advances in the treatment of ovarian cancer, including research using PARP inhibitors,...
by CheckRare Staff | Nov 15, 2025
Philip Molyneaux, MD, PhD, a Professor of Interstitial Lung Disease (ILD) at Imperial College London and the Asthma+Lung UK Chair of Respiratory Research at Royal Brompton Hospital, where is also the Director of the UK National Institute for Health and Care Research...
by CheckRare Staff | Oct 29, 2025
Accurate diagnosis and treatment of epilepsy challenges the medical community, patients, and their loved ones.[1] As many as one third of patients have seizures that are inadequately controlled with available therapies, and treatment response is highly variable.[2,3]...
by CheckRare Staff | Oct 21, 2025
A Spotlight on Two Main Subtypes: Mycosis Fungoides and Sézary Syndrome Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders.[1] Cutaneous T-cell lymphoma is a rare group of malignancies,...
by CheckRare Staff | Oct 3, 2025
Jacky Smith, MB, ChB, FRCP, PhD, Chair of Respiratory Medicine at the University of Manchester, discusses topline results from the phase 2a RIVER trial for patients with refractory chronic cough (RCC). Topline results and a responder analysis from the RIVER...
